Cargando...
DYRK2 controls a key regulatory network in chronic myeloid leukemia stem cells
Chronic myeloid leukemia is a hematological cancer driven by the oncoprotein BCR-ABL1, and lifelong treatment with tyrosine kinase inhibitors extends patient survival to nearly the life expectancy of the general population. Despite advances in the development of more potent tyrosine kinase inhibitor...
Gardado en:
| Publicado en: | Exp Mol Med |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Nature Publishing Group UK
2020
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8080801/ https://ncbi.nlm.nih.gov/pubmed/33067577 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s12276-020-00515-5 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|